Navigation Links
FDA Re-Inspection Results in Positive Re-Classification of Guayama,Facility

MADISON, N.J., May 9 /PRNewswire-FirstCall/ -- Wyeth (NYSE: WYE) today announced that the U.S. Food and Drug Administration's (FDA) San Juan District Office has informed the Company that the recent FDA re-inspection of its Guayama, Puerto Rico manufacturing facility has resulted in a positive re- classification of the site. The new classification means that any issues found by the FDA have either been corrected by the Company or do not merit any further regulatory action. Guayama will continue to serve as a strategic manufacturing site and a source for future Wyeth products.

"We are pleased that FDA has re-classified the Guayama facility and we were able to resolve its concerns in a satisfactory manner. The change in status allows for the timely approval of new products manufactured at the site," says Bernard Poussot, President, Chief Operating Officer and Vice Chairman, Wyeth. "We are committed to maintaining the highest standards of quality and compliance in our manufacturing operations around the world."

This re-inspection was related to the Warning Letter FDA sent to Wyeth in May 2006 regarding several specific concerns about manufacturing at Guayama.

Wyeth is one of the world's largest research-driven pharmaceutical and health care products companies. It is a leader in the discovery, development, manufacturing and marketing of pharmaceuticals, vaccines, biotechnology products and non-prescription medicines that improve the quality of life for people worldwide. The Company's major divisions include Wyeth Pharmaceuticals, Wyeth Consumer Healthcare and Fort Dodge Animal Health.

The statements in this press release that are not historical facts are forward-looking statements based on current expectations of future events and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These risks and
'"/>




Page: 1 2 3

Related medicine technology :

1. Point of Care Cardiac Analyzers Yield Rapid Cardiac Marker Results
2. Diagnosing Diabetes: Immediate HbA1c Results Improve Glycemic Control
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
5. Positive Aggrastat Results Featured in the Journal of the American College of Cardiology
6. Pixantrone Combination Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Results in Reduction in Severe Toxicities Including Heart Damage When Compared to Doxorubicin-based Therapy
7. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
10. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
11. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
Post Your Comments:
(Date:12/2/2008)...if., Dec. 2 TorreyPines Therapeuti...e results from a 26 patient Phase II trial evaluat...tomia, or dry mouth, in patients with Sjogren,s sy...istically significant increase in salivary flow pr...0 mg, 15 mg, and 20 mg. These doses were safe and ...
(Date:12/2/2008)... Dec. 2 Horizon Therapeutics, Inc....ay announced that two pivotal,Phase 3 trials eval... HZT-501,met all primary endpoints. HZT-501, a n...containing ibuprofen and famotidine, demonstrated ...dence of non-steroidal,anti-inflammatory drug (NS...
(Date:12/2/2008)..., Dec. 2 Micromet, Inc. ...eloping novel, proprietary antibodies for the trea...ses, today announced that it has entered into an a...Facility (CEFF) with Kingsbridge Capital Limited, ...e agreement, Kingsbridge has committed to provide ...
(Date:12/1/2008)... 2 New research has fou... computed tomography (CT) scanner in an emergency ...ke victims who receive a potentially life-saving t... Shore Medical Center (NSMC)-Salem Hospital in Sal...eeting of the Radiological Society of North Americ...
Breaking Medicine Technology:TorreyPines Therapeutics Muscarinic Agonist NGX267 Meets Primary Endpoint in a Phase II Clinical Trial in Patients with Xerostomia 2TorreyPines Therapeutics Muscarinic Agonist NGX267 Meets Primary Endpoint in a Phase II Clinical Trial in Patients with Xerostomia 3TorreyPines Therapeutics Muscarinic Agonist NGX267 Meets Primary Endpoint in a Phase II Clinical Trial in Patients with Xerostomia 4TorreyPines Therapeutics Muscarinic Agonist NGX267 Meets Primary Endpoint in a Phase II Clinical Trial in Patients with Xerostomia 5Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints 2Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints 3Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints 4Micromet Expands Committed Equity Financing Facility to $75 Million 2Micromet Expands Committed Equity Financing Facility to $75 Million 3Micromet Expands Committed Equity Financing Facility to $75 Million 4Micromet Expands Committed Equity Financing Facility to $75 Million 5Micromet Expands Committed Equity Financing Facility to $75 Million 6Portable CT Increases Chance of Stroke Survival and Recovery 2Portable CT Increases Chance of Stroke Survival and Recovery 3NCPA Applauds U S House Vote in Favor of H R 6331 22698 1New Aptivus 28R 29 28tipranavir 29 Oral Solution Approved for Treatment Experienced Pediatric and Adolescent HIV Patients 6198 1New Aptivus 28R 29 28tipranavir 29 Oral Solution Approved for Treatment Experienced Pediatric and Adolescent HIV Patients 6198 2New Aptivus 28R 29 28tipranavir 29 Oral Solution Approved for Treatment Experienced Pediatric and Adolescent HIV Patients 6198 3New Aptivus 28R 29 28tipranavir 29 Oral Solution Approved for Treatment Experienced Pediatric and Adolescent HIV Patients 6198 4New Aptivus 28R 29 28tipranavir 29 Oral Solution Approved for Treatment Experienced Pediatric and Adolescent HIV Patients 6198 5New Aptivus 28R 29 28tipranavir 29 Oral Solution Approved for Treatment Experienced Pediatric and Adolescent HIV Patients 6198 6New Aptivus 28R 29 28tipranavir 29 Oral Solution Approved for Treatment Experienced Pediatric and Adolescent HIV Patients 6198 7New Aptivus 28R 29 28tipranavir 29 Oral Solution Approved for Treatment Experienced Pediatric and Adolescent HIV Patients 6198 8New Aptivus 28R 29 28tipranavir 29 Oral Solution Approved for Treatment Experienced Pediatric and Adolescent HIV Patients 6198 9Drug Coated Stents Reduce Repeat Artery Procedures 22693 1Drug Coated Stents Reduce Repeat Artery Procedures 22693 2Drug Coated Stents Reduce Repeat Artery Procedures 22693 3Certain anti cancer agents could be harmful to patients with heart disease 22689 1Certain anti cancer agents could be harmful to patients with heart disease 22689 2Certain anti cancer agents could be harmful to patients with heart disease 22689 3
...URG, Germany, May 10th, 2007 - Antisense,Pharma, a...argeted,therapies for malignant tumors, today anno...12009 in high-grade glioma will be,presented at th...linical Oncology (ASCO), which will be held in Chi...he open-label, randomized dose-finding Phase,IIb-t...
...praisal Committee concludes that alteplase is clin... 14 May 2007 – A new clinical appraisal,publ...nical,Excellence (NICE) in the UK has recommended ... with acute ischaemic stroke, based on,its clinica...tive,care alone.1 Alteplase is marketed as Actilys...
Other Medicine Technology:2007 ASCO Annual Meeting: Clinical Results on Phase IIb-study with,AP 12009 in Anaplastic Astrocytoma selected for Poster Discussion 22007 ASCO Annual Meeting: Clinical Results on Phase IIb-study with,AP 12009 in Anaplastic Astrocytoma selected for Poster Discussion 3Actilyse (alteplase) Recommended by National Institute for Health,and Clinical Excellence for Treatment of Acute Ischaemic Stroke 2Actilyse (alteplase) Recommended by National Institute for Health,and Clinical Excellence for Treatment of Acute Ischaemic Stroke 3Actilyse (alteplase) Recommended by National Institute for Health,and Clinical Excellence for Treatment of Acute Ischaemic Stroke 4Actilyse (alteplase) Recommended by National Institute for Health,and Clinical Excellence for Treatment of Acute Ischaemic Stroke 5
(Date:12/2/2008)...SANTA BARBARA, Calif., Dec. 2 Bio...g products and services, and Alere(R) , who provi..., productivity improvement and complex care manage...trophic conditions to health plans, employers, and... BioIQ,s home-test kits and online reporting tools...
(Date:12/2/2008)...LONDON, Dec. 2 Services form an in...turers, (OEMs,) revenues. It has therefore become,...edical imaging services,market to remain competit...tract penetration rates. , (Logo: http://... New analysis from Frost & Sullivan ( htt...
(Date:12/2/2008)... SPEAK to collect and dis... Bellevue, Wash. (PRWEB) Dece...nnounced the launch of a new initiative to focus p... awareness . The official kick-off of SPEAK will o...Pharmacists (ASHP) 2008 Midyear Clinical Meeting, ...
(Date:12/2/2008)... Xena Health and Solution...l Claims Service "Claims in a Cloud" as ...sgow and London (PRWEB) December 2, 2008 -- Making...s to the launch of the first phase of a "Cl... solution from Corporate Modelling partners Xena ...
Breaking Medicine News(10 mins):Health News:BioIQ and Alere to Provide At-Home Biometric Screening Tests to Employees 2Health News:Encouraging Prospects for Medical Imaging Equipment Services in Europe 2Health News:Encouraging Prospects for Medical Imaging Equipment Services in Europe 3Health News:Pharmacy OneSource Launches SPEAK Initiative to Promote Medication Safety Awareness 2Health News:Corporate Modelling Partners Start Selling BPM in Cloud Service 2
...holesterol can do to people. High-fat diets cause ...re looking at food labels // to know what they con... easier for consumers to avoid trans fats, which p...ked to an increased risk of heart disease, among o...
...e a greater risk of developing Alzheimer’s, the de...stralian researchers // has claimed. The researc...delphia and the Edith Cowan University in Western ...e 'almost certainly' increases risk from Alzheimer...
...y among the people of Queensland when it comes to ...okesman for Queensland Institute of Medical Resear...drive against skin cancer is not having the desire...MR did not elicit the expected number of responses...
...nd are seeking legal protection in the event of a ...n they would be compelled to work // under adverse...ety (OSH) regulations in force in the country are ... sued as per the law. This is very much likely w...
Other Medicine News:Health News:Food labels to include information on trans fats in US 2Health News:Food labels to include information on trans fats in US 3Health News:Obesity could lead to Alzheimer's 2
...iciency and quality to routine urine microscopic a...luorescent flow cytometry with fully automated uri...processing are easily accommodated by the rack-bas... high volume laboratories. Fluorescent flow cytom...
... is a single-use, disposable needle loading device... a Bard BrachyStar needle for interstitial seed im...on safety shield, inner compartment that holds see...lded fitting that connects the cartridge to the ne...
...System uses technology developed by Mortara, the c... digital Holter recorder in 1994. This true 12-lea...r study provides superior ST segment analysis. ,...l recorder allows a full 24-hour 12-lead study to ...
Data review and analysis is carried out with the Acquidata Uromac software already supplied with Acquidata Uromac Lab based urodynamics systems
Medicine Products: